{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-205615","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.968383+00:00","generated_at":"2026-06-12T03:01:08.705680+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MAIA Biotech Q2 net loss $4.5M; THIO-101 Phase 2 DCR 82%, 35 patients enrolled","bullets":["Cash $9.1M at June 30, 2023; net loss $4.5M for Q2 2023 vs $3.3M loss in Q2 2022.","R&D expenses $2.6M, G&A $2.0M for the quarter.","THIO-101 Phase 2: 35 patients dosed as of July 2023; preliminary DCR 82% (9 of 11 patients) at first assessment.","First 2 patients alive without progression 10.2 and 8.5 months post-treatment, no additional therapy needed.","Filed second provisional patent for third telomere-targeting molecule MAIA-2021-029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-205615","json":"https://secwatch.observer/filing/0001193125-23-205615.json","markdown":"https://secwatch.observer/filing/0001193125-23-205615.md","text":"https://secwatch.observer/filing/0001193125-23-205615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/0001193125-23-205615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/d514056d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:01:08.705680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecc78055064bead781efb55e89eafb8fd045878c","claim":"MAIA Biotechnology, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3.","evidence_excerpt":"MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/0001193125-23-205615-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}